A comparative efficacy and safety study of clarithromycin, roxithromycin and erythromycin stearate in mild pneumonia

Basit Öğe Kaydı
dc.authorwosid, osman/HRD-6024-2023
dc.authorwosid, Osman/AGR-7980-2022
dc.contributor.authorHatipoglu, ON
dc.contributor.authorTasan, Y
dc.date.accessioned2024-06-12T10:56:36Z
dc.date.available2024-06-12T10:56:36Z
dc.date.issued2000
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe efficacy and safety of clarithromycin, roxithromycin and erythromycin stearate in mild pneumonia were compared in an open randomized trial. Eighty-six male patients, doing their obligatory military service, ranging between 19 and 24 years of age (mean 20), were randomly treated: 29 with clarithromycin 500 mg 12-hourly, 30 with roxithromycin 150 mg 12-hourly, and 27 with erythromycin stearate 500 mg 6-hourly, each course being administered for 10 days. Seventy-eight patients were able to be evaluated for efficacy, 28 receiving clarithromycin, 28 roxithromycin, and 22 erythromycin stearate. There were no significant differences among the groups in terms of clinical success rates (clinical cure or improvement: 89% for clarithromycin, 82% for roxithromycin, and 73% for erythromycin stearate, p = 0.32). However, we found chat there were significant differences among the groups in terms of clinical cure rates (75% for clarithromycin, 64% for roxithromycin, and 41% for erythromycin stearate, p = 0.04). Adverse events, mostly gastrointestinal, caused discontinuation of treatment in 3.4% of the patients in the clarithromycin group, in 6.6% of the patients in the roxithromycin group, and in 18.5% of the patients in the erythromycin stearate group. The results indicate that there were no statistically significant differences among the three treatment groups in terms of clinical success rates, but that clarithromycin and roxithromycin were better tolerated.en_US
dc.identifier.doi10.3349/ymj.2000.41.3.340
dc.identifier.endpage344en_US
dc.identifier.issn0513-5796
dc.identifier.issue3en_US
dc.identifier.pmid10957888en_US
dc.identifier.scopus2-s2.0-0033855984en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage340en_US
dc.identifier.urihttps://doi.org/10.3349/ymj.2000.41.3.340
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19857
dc.identifier.volume41en_US
dc.identifier.wosWOS:000088021100007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherYonsei Univ College Medicineen_US
dc.relation.ispartofYonsei Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectClarithromycinen_US
dc.subjectErythromycin Stearateen_US
dc.subjectRoxithromycinen_US
dc.subjectPneumoniaen_US
dc.subjectCommunity-Acquired Pneumoniaen_US
dc.subjectGuidelinesen_US
dc.subjectManagementen_US
dc.subjectAdultsen_US
dc.titleA comparative efficacy and safety study of clarithromycin, roxithromycin and erythromycin stearate in mild pneumoniaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu